ACTRN12622000064707
Recruiting
未知
A phase II trial examining the safety and preliminary efficacy of repetitive transcranial magnetic stimulation (rTMS) for people living with multiple sclerosis
niversity of Tasmania0 sites108 target enrollmentJanuary 20, 2022
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Multiple Sclerosis
- Sponsor
- niversity of Tasmania
- Enrollment
- 108
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosed of Multiple Sclerosis (MS) by a neurologist,
- •Has been stable (on or off MS treatment) and relapse free for 6 months
- •Extended Disability Status Scale (EDSS) between 1\.5 and 6
- •Has capacity to provide informed consent
- •Able to travel to site every weekday for 4 weeks
Exclusion Criteria
- •Have metal inside their head or body (i.e. cardiac pacemaker)
- •Pregnant or intend to become pregnant
- •Have a history of seizures, epilepsy, serious head trauma\*, substance abuse\*, stroke, brain surgery, bipolar, mania, claustrophobia or migraines
- •Have an EDSS \< \= 1 and \> \= 6\.5
- •Previously received rTMS therapy
- •English illiterate\*\* (to enable completion of follow up questionnaires)
- •Currently involved in another interventional clinical trial
- •\*Note: participants with minor/moderate head trauma, previous substance abuse and/or well controlled or rare migraines may be included on PI discretionary basis, e.g. these conditions are prevalent in the community and may not be clinically significant. \*\*English illiterate participants who can provide a suitable translator/interpreter for the duration of the study (including phone calls, questionnaires, and visits) may be included.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A clinical trial investigating how effective and safe the combination of drugs rituximab and pembrolizumab is at treating patients with Waldenström's Macroglobulinaemia that have not responded to their initial treatment or their disease has come back after being treated.Relapsed and refractory Waldenström's MacroglobulinaemiaMedDRA version: 21.0Level: PTClassification code 10047801Term: Waldenstrom's macroglobulinaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001767-23-GBniversity College London42
Active, not recruiting
Phase 1
A clinical trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-004506-10-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI69
Active, not recruiting
Phase 1
A phase II trial to evaluate the safety and activity of single-agent lenalidomide given as maintenance therapy after response to second-line therapy in patients with relapsed diffuse large B cell lymphoma, not eligible for high-dose chemotherapy and autologous transplantation [Lenalidomide and DLBCL - NDpatients affected by diffused linfoma with big cellsMedDRA version: 9.1Level: LLTClassification code 10012818Term: Diffuse large B-cell lymphomaEUCTR2008-003729-18-ITOSPEDALE S. RAFFAELE38
Not yet recruiting
Phase 2
A Phase II Trial to Evaluate the Safety and Efficacy of clazakizumab for the desensitisation of highly sensitized patients on the deceased donor kidney transplant waiting listEnd stage kidney diseaseRenal and Urogenital - Kidney diseaseACTRN12624000567527Royal Melbourne Hospital10
Recruiting
Not Applicable
Exercise during CHemotherapy for Recurrent Ovarian cancer (ECHO-R)Recurrent Ovarian CancerCancer - Ovarian and primary peritonealACTRN12621000042842Griffith University80